Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients

Archives of General Psychiatry

Volumn 65, Issue 10, 2008, Pages 1214-1221

  Zarkin, Gary A ^a,c   Bray, Jerany W ^a,c   Aldridge, Arnie ^a,c   Mitra, Debanjali ^a,c   Mills, Michael J ^a,c   Couper, David J ^a,b,c   Cisler, Ron A ^a,c,d  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of Wisconsin School of Medicine and Public Health ^*

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; NALTREXONE; PLACEBO;

ADULT; ALCOHOLISM; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; UNITED STATES;

ADULT; ALCOHOL DETERRENTS; ALCOHOLISM; BEHAVIOR THERAPY; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; TAURINE; TEMPERANCE;

EID: 53849104641     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.65.10.1214     Document Type: Article

References (28)

1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291(10):1238-1245.
2. [published corrections appear in JAMA. 2005;293(3):293-294 and 298]
3. Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: estimates, update methods, and data. Reported in: Harwood H, Fountain D, Livermore G. The Economic Costs of Alcohol and Drug Abuse in the United States 1992. Rockville, MD: National Institutes of Health; 1998. NIH publication No. 98-4327.
4. Longabaugh R, Zweben A, LoCastro JS, Miller WR. Origins, issues and options in the development of the combined behavioral intervention. J Stud Alcohol Suppl. July 2005;(15):179-187.
5. Litten RZ, Allen JP. Advances in the development of medications for alcoholism treatment. Psychopharmacology (Berl). 1998;139(1-2):20-33.
6. Mason BJ, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr. 2000;5(2):58-69.
7. The COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003;27(7):1107-1122.
8. Mattson ME, Litten RZ. Combining treatments for alcoholism: why and how? J Stud Alcohol Suppl. July 2005;(15):6-16.
9. Pettinati HM, Weiss RD, Dundon W, et al. A structured approach to medical management: a psycho social intervention to support pharmacotherapy inthetreatment of alcohol dependence. J Stud Alcohol Suppl. July 2005;(15):168-178.
10. Swift R, Pettinat HM. Choosing pharmacotherapies for the COMBINE Study: process and procedures; an investigational approach to combination pharmaco-therapy for the treatment of alcohol dependence. J Stud Alcohol Suppl. July 2005; (15):140-147.
11. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gast-friend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A; COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE Study; a randomized controlled trial. JAMA. 2006;295(17):2003-2017.
12. UKATT Research Team. Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT). BMJ. 2005; 331(7516):544-548.
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
14. Zarkin GA, Bray JW, Mitra D, Cisler RA, Kivlahan DR. Cost methodology of COMBINE. J Stud Alcohol Suppl. July 2005;(15):50-55.
15. Ingenix, Inc. The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes. Salt Lake City, UT: Ingenix Inc; 2005.
16. Cisler RA, Zweben A. Development of a composite measure for assessing alcohol treatment outcome. Alcohol Clin Exp Res. 1999;23(2):263-271.
17. Miller WR, Tonigan JS, Longabaugh R. The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 1995.
18. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR; Panel on Cost-effectiveness in Health and Medicine. Guidelines for pharmacoeconomic studies: recommendations from the Panel on Cost-effectiveness in Health and Medicine. Pharmacoeconomics. 1997;11(2):159-168.
19. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. New York, NY: Oxford University Press; 2005.
20. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10(8):779-787.
21. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006;6(1):52-59.
22. Thomson MicroMedex. RedBook for Windows. Version 61127, Vol 41. Montvale, NJ: Thomson PDR; July 2006.
23. Mobley LR, Hoerger TJ, Wittenborn JS, Galuska DA, Rao JK. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate. Med Decis Making. 2006;26(2):194-206.
24. DiSantostefano RL, Biddle AK, Lavelle JP. The long-term cost effectiveness of treatments for benign prostatic hyperplasia. Pharmacoeconomics. 2006;24 (2):171-191.
25. Poldrugo F, Haeger DA, Comte S, Walburg J, Palmer AJ. A critical review of pharmacoeconomic studies of acamprosate. Alcohol Alcohol. 2005;40(5):422-430.
26. Palmer AJ, Neeser K, Weiss C, Brendt A, Comte S, Fox M. The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol. 2000;35(5):478-492.
27. Schädlich PK, Brecht JG. The cost effectiveness of acamprosate in the treatment of alcoholism in Germany: economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study. Pharmacoeconomics. 1998;13(6):719-730.
28. Rychlik R, Siedentop H, Pfeil T, Daniel D. Cost-effectiveness of adjuvant treatment with acamprosate in maintaining abstinence in alcohol dependent patients. Eur Addict Res. 2003;9(2):59-64.